Introduction

Background: CPT plus NXL is a cephalosporin-noraphylxine 2-β-lactamase inhibitor combination against Gram-positive and Gram-negative pathogens. There is limited in vitro and in vivo evidence with CPT and S. pyogenes. The combination of CPT and NXL, CAI, is currently in early clinical development.

Materials and Methods: An IVPKM was used to simulate two human dose regimens and measure their effect on strains of Enterobacteriaceae. Regimen 1: CPT 400 mg (C

Pharmacokinetics

Comparison of the Antibacterial Effects of Two Dosing Regimens of Cefaroline in Combination With NXL104 Against Enterobacteriaceae

Comparison of the Antibacterial Effects of Two Dosing Regimens of Cefaroline in Combination With NXL104 Against Enterobacteriaceae

Conclusions: The ABE of CPT 400 mg and CPT 600 mg plus NXL 600 mg against E. coli ATCC 25922 was similar, but the CPT 600 mg/NXL 600 mg regimen showed a statistically significant advantage against the E. coli CTX-M producer with suppression of growth (CPT/NXL MIC 0.08 mg/L).

References


